Maybe tap 200 and fall back down?Would look to add on that trendline, could get explosive above 200 IMO
VRTX trade ideas
$VRTX BOFA initiates Vertex with BUY and $220 target.Entry level $179 = Target price $190 = Stop loss $174
Momentum and RSi are extremely strong.
Above $178 bullish trade entry having cleared MA resistance.
Earnings approaching, possible stimulant.
Vertex initiated at BofA/Merrill Vertex reinstated with a Buy at BofA/Merrill. BofA/Merrill analyst Geoff Meacham reinstated coverage of Vertex with a Buy rating and $220 price target, citing the company's differentiated growth profile, upside potential in the upcoming triple combination therapy launch, and an emerging orphan disease pipeline.
thefly.com
Vertex’s shares have lost 0.6% over the past three months compared with the Zacks Biomedical and Genetics industry’s decline of 4.7%. The Zacks analyst believes that Vertex’s third cystic fibrosis (CF) medicine, Symdeko, in a very short time, has become the main driver of its CF revenues.
Vertex rapidly advanced its triple combination CF regimen through late-stage development and regulatory filings. The regimen is crucial for long-term growth as it has the potential to treat up to 90% of CF patients. Meanwhile, Vertex’s non-CF pipeline, though early stage, looks interesting with several pipeline readouts expected in 2020-21.
However, competitive pressure is rising in the CF market with many other companies developing triple combo CF drugs. Also, Vertex’s dependence on just the CF franchise for growth is a concern. Shares have outperformed the industry this year so far. Estimates have gone up slightly ahead of Q3 earnings. Vertex has a positive record of earnings surprises in the recent quarters.
Source ZACKS.com
$VRTX High call buying with 25% potential gain by MAY 24thThis is not a name we are overly familiar with but in the past few weeks, we have noticed numerous upgrades and some large funds increasing exposure in the name. Finally higher than normal option activity was spotted on Friday with a significant upside return on the strike price. Like all Pharma stocks good news can be very good for the stock price, so keep watch.
VERTEX PHARMACEUTICALS INC.
Vertex Pharmaceuticals, Inc. engages in the business of discovering, developing, manufacturing and commercializing small molecule drugs for patients with serious diseases. It focuses on development and commercializing therapies for the treatment of cystic fibrosis, infectious diseases including viral infections such as influenza and bacterial infections, autoimmune diseases such as rheumatoid arthritis, cancer, inflammatory bowel disease and neurological disorders including pain and multiple sclerosis
Vertex Pharma $VRTX weekly cup & handle in rising channelA favorite large cap Biotech into 2019 setting up for potential upside continuation
***PERFECT SHORT SETUP***NASDAQ:VRTX Sell short below yesterday's low. see my notes on the chart.
Please like, comment and follow if you like my ideas. THANK YOU!!!
Please note that this information is not a recommendation to buy or sell. It is to be used for educational purposes only.
$VRTX Overbought - Shooting Star Confirmed$VRTX Overbought - beginning to retrace today closing well below yesterday's low, confirming bearish shooting star reversal candle from yesterday. Will be looking for additional 8-10% downside from today's close to the area of the 200d ema near term. (More downside possible depending on outcome of Feb ER)
Target: $170-$175 range by mid February
Also of note, in fundamental news...Vertex just announced today they have terminated their COO/interim CFO as "the result of personal behavior that violated Vertex's Code of Conduct and values" - possibly more fuel to power this latest downward move. Expect a gap down at the open tomorrow morning.
Note: Informational analysis, not investment advice.
[VRTX] phase 2The slope of 30MM is positive, and the price is going up. If the price breaks de resistant, it will confirm phase 2.
($VRTX) Vertex: a buy only after a break outVertex has consolidating the price in a bullish wedge. A key resistence zone is at 178.57, a break out of such edge is interesting because it might pull up the price toward new high records. Stock is under the radar
$VRTX Reversing Off Upper Channel Limit$VRTX Vertex looking over-extended, reversing off the long term upper channel limit. Barring an earnings home run next week, expecting further price correction in the coming weeks and months.
Medium term target: $163.50
Long term target: $153.50 (lower channel support)
Earnings next week, 7/25
Note: Observation/opinion, not investment advice.
VRTX - trade set upShort trap city!!! right now it's opening at 161.. This should run for even a swing trade for a few days. I love this gap and trap!!!!
VRTX making a possible come backAfter the sell off in June the stock crossed into the oversold territory and is trying to reverse the trend upwards. The second long signal is the breaking above the downward resistance line, if it continues in the current course and breaks above 200MA this will signal a strong reversal.
#VRTX #long #stockVRTX looks good. not only is there an inverse H&S there is a zig zag up. Looking for a $177 target. Will probably look at the april options at the money call. look to enter with a limit order of $7.00 at a strike $170 with expiry of 13 April 2018.
Another nice setup on $VRTX - C&H +65 pts potential moveHeld that 136 level like a champ while working on the handle (which is a mini cup by itself). Good numbers will confirm and send this on a 65 pts journey, probably higher
VRTX Pullback Bounce off the 20SMATook a swing trade on this stock on a pullback buy at an entry of 123.58 with a target of 130.69. This stock has started to pull back a bit from my entry but I am still in the green on the play. Looking for a bounce off the 20SMA for a push to the target. What you all think? Feedback is always encouraged and appreciated.
